Maze Therapeutics Director Reports 16,000‑Share Option Grant

Rhea-AI Filing Summary

Maze Therapeutics director Neil Exter reported acquisition of an option to purchase 16,000 shares of Maze Therapeutics, Inc. (MAZE). The option has an exercise price of $13.35 and was reported with a transaction date of 08/17/2025. The option becomes exercisable beginning 08/16/2035 per the table, and 16,000 underlying shares are associated with the award. The filing explains the option vests monthly after an initial partial vesting of 1/16th on March 3, 2025, subject to continued service. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Positive

• Director reported acquisition of a stock option covering 16,000 shares, showing continued equity alignment with the company.
• Clear vesting schedule disclosed: initial 1/16th vesting on March 3, 2025, then monthly vesting thereafter subject to continued service.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received a time‑based stock option for 16,000 shares at $13.35; transaction appears routine and service‑conditioned.

The Form 4 discloses a non‑derivative disclosure of a stock option award that vested incrementally, with an initial 1/16th vesting on March 3, 2025 and monthly thereafter, subject to continued service. The option strike is $13.35 and the underlying amount is 16,000 shares. This is a standard executive/director equity compensation disclosure and, by itself, does not indicate a change in control, financing, or material corporate event.

Corporate Governance Expert

TL;DR: Disclosure documents routine insider equity compensation and shows continued director alignment with shareholders via vested options.

The filing shows the reporting person is a director and that the award vests incrementally based on continued service, which aligns director incentives with long‑term company performance. The document is properly signed by an attorney‑in‑fact and includes vesting explanation. There are no indications of unusual acceleration, transfer, or related‑party transactions disclosed in this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Exter Neil

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.35	08/17/2025		A		16,000		(1)	08/16/2035	Common Stock	16,000	$0	16,000	D

Explanation of Responses:

1. The option vested as to 1/16th of the total award on March 3, 2025, and thereafter vested or vests as to an additional 1/16th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Maze Therapeutics (MAZE) disclose in this Form 4?

The filing reports that director Neil Exter acquired a stock option to buy 16,000 shares with an exercise price of $13.35, transaction dated 08/17/2025.

When does the option vest and when is it exercisable for MAZE?

The option vested 1/16th on March 3, 2025 and vests monthly thereafter subject to continued service; the table lists an exercisable/expiration reference to 08/16/2035 for the underlying shares.

Who filed the Form 4 for MAZE and when was it signed?

The Form 4 was signed by Courtney Phillips as attorney‑in‑fact on 08/19/2025.

Does this Form 4 indicate any sale or disposition of MAZE shares?

No. The filing reports an acquisition/award of a stock option; there is no disclosed sale or disposition of shares in this Form 4.

Does the filing show any unusual terms or related‑party transactions for MAZE?

No unusual acceleration, transfer, or related‑party transaction is disclosed; the filing describes a standard service‑conditioned vesting schedule.